Cargando…

Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole

Aripiprazole is a second-generation antipsychotic with a unique pharmacologic receptor profile that has efficacy in the treatment and prevention of mania in bipolar I disorder. This article reviews the evidence supporting treatment of adults with bipolar I disorder using aripiprazole as monotherapy...

Descripción completa

Detalles Bibliográficos
Autor principal: Muzina, David J
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695233/
https://www.ncbi.nlm.nih.gov/pubmed/19557122
_version_ 1782168174421082112
author Muzina, David J
author_facet Muzina, David J
author_sort Muzina, David J
collection PubMed
description Aripiprazole is a second-generation antipsychotic with a unique pharmacologic receptor profile that has efficacy in the treatment and prevention of mania in bipolar I disorder. This article reviews the evidence supporting treatment of adults with bipolar I disorder using aripiprazole as monotherapy or adjunctively during acute mania and its utility as an intramuscular agent for agitation in manic patients. Results from one of the longest bipolar maintenance trials which support aripiprazole as a prophylactic mood stabilizer, specifically against manic relapses, will be discussed as well as a post-hoc analysis that suggests efficacy for rapid cycling bipolar disorder. Safety and tolerability issues, patient-focused perspectives and aripiprazole’s place in therapy for bipolar mania will be covered.
format Text
id pubmed-2695233
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26952332009-06-16 Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole Muzina, David J Neuropsychiatr Dis Treat Expert Opinion Aripiprazole is a second-generation antipsychotic with a unique pharmacologic receptor profile that has efficacy in the treatment and prevention of mania in bipolar I disorder. This article reviews the evidence supporting treatment of adults with bipolar I disorder using aripiprazole as monotherapy or adjunctively during acute mania and its utility as an intramuscular agent for agitation in manic patients. Results from one of the longest bipolar maintenance trials which support aripiprazole as a prophylactic mood stabilizer, specifically against manic relapses, will be discussed as well as a post-hoc analysis that suggests efficacy for rapid cycling bipolar disorder. Safety and tolerability issues, patient-focused perspectives and aripiprazole’s place in therapy for bipolar mania will be covered. Dove Medical Press 2009 2009-05-20 /pmc/articles/PMC2695233/ /pubmed/19557122 Text en © 2009 Muzina, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Expert Opinion
Muzina, David J
Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole
title Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole
title_full Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole
title_fullStr Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole
title_full_unstemmed Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole
title_short Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole
title_sort treatment and prevention of mania in bipolar i disorder: focus on aripiprazole
topic Expert Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695233/
https://www.ncbi.nlm.nih.gov/pubmed/19557122
work_keys_str_mv AT muzinadavidj treatmentandpreventionofmaniainbipolaridisorderfocusonaripiprazole